摘要
目的观察非布司他治疗尿酸性肾病的临床疗效。方法选取我院2014年10月-2016年2月收治的66例患者,随机平行分为对照组和治疗组。对照组采用别嘌醇片治疗,治疗组采用非布司他片治疗,按照非布司他给药量不同,治疗组随机分两组,治疗A组(40 mg)与B组(80 mg);对比组间指标变化及不良反应情况。结果A组、B组、对照组可分别使35.1%、68.7%、33.4%患者的尿酸下降至360μmol/L以下,B组疗效显著优于A组与对照组(P<0.05),A组与对照组疗效相当。A组与B组分别使尿酸降低(43.2±21.6)%和(53.4±18.7)%,B组显著优于对照组(44.2±15.1)%(P<0.05),A组与对照组疗效相当。肾小球滤过率、血肌酐、24 h尿蛋白定量比较,组间比较差异有统计学意义(P<0.05),具体为A组与B组、A组与对照组以及B组与对照组。三组不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用非布司他治疗尿酸性肾病,不仅能降低患者血尿酸,还能起到保护肾脏的作用,效果较好,值得临床推广。
Objective To observe the clinical effect of Febuxosta on uric acid nephropathy. Methods 66 patients admitted to our hospital from October 2014 to February 2016 were randomly divided into control group and treatment group in equal number. The control group was treated with allopurinol tablets, and the treatment group with Febuxosta. The latter group was subdivided into groups A and B based on the two dosages: 40 mg and 80 rag, respectively. The index changes and adverse reactions were compared between the groups. Results he uric acid among respective 35.1% , 68.7% and 33.4% of the patients in group A, group B and control group was decreased to below 360 μmol/L: The effect of B group was signifi- cantly better than the other two groups ( P 〈 0.05 ) and group A and the control group presented the same curative effect. In Group A and B, the uric acid was decreased by (43.2 ± 21.6) % and (53.4 ±18.7 ) % , respectively. Group B was signifi- cantly better than the control group (44. 2 ± 15. 1 )% (P 〈 0. 05 ) , but Group A and the control group showed insignificant difference in curative effect. There were significant differences between the three groups in terms of glomerular filtration rate, serum creatinine, 24 - hour urine protein quantitative comparison ( P 〈 0.05 ) but no significant difference in terms of the in- cidence of adverse reactions between them ( P 〉 0. 05 ). Conclusion Febuxosta may reduce uric acid in the patients with u- ric acid nephropathy. On the other hand, it may act to protect kidneys effectively.
出处
《现代医院》
2016年第9期1260-1262,1266,共4页
Modern Hospitals
基金
江西省科技支撑计划项目(编号:2015ZBBG70020)
关键词
非布司他
尿酸性肾病
临床疗效
Febuxosta
Uric Acid Nephropathy
Clinical Curative Effect